Results 51 to 60 of about 3,499 (203)

Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria

Malaria Journal, 2002
We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa.
Warhurst David C, Adagu Ipemida S, Butcher Geoffrey A, Fivelman Quinton L, Pasvol Geoffrey   +4 more
doaj   +1 more source

Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction [PDF]

, 2010
Background Drug resistance determination for Plasmodium falciparum infections are important to determining the type of treatment to be given. Besides in vivo experiments, molecular methods, such as sequencing and PCR, are now increasingly being used ...
Linda Gan, Jin Loh
core   +2 more sources

Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana, Israel Ehizuelen Ebhohimen, Moses Okpeku, Jess Vergis   +3 more
wiley   +1 more source

Malaria: 11‐Year Experience With Imported Cases at a German University Hospital and Epidemiological Trends Amid the COVID‐19 Pandemic

Journal of Parasitology Research, Volume 2026, Issue 1, 2026.
Background By the mid‐20th century, Europe eradicated endemic malaria. However, the significance of imported infections in nonendemic regions is growing. These cases often constitute the majority, can sustain transmission, trigger relapses, and increase mortality in these areas. Methods We conducted a retrospective, single‐center study of patients with
Patricia Mester, Claudia Kunst, Stephan Schmid, Katharina Zimmermann, Sigrid Bülow, Janine Rennert, Benedikt M. J. Lampl, Tobias Schilling, Martina Müller, Vlad Pavel, Satabdi Datta Choudhury   +10 more
wiley   +1 more source

Efficacy and Tolerability of Antimalarials and Molecular Resistance Markers of Falciparum Malaria in Jimma Region, Ethiopia [PDF]

, 2011
Due to increasing drug resistance, artemisinin-based combination chemotherapy (ACT) has become the first-line treatment of falciparum malaria in many endemic countries.
Eshetu, Teferi
core  

Preventing malaria in international travellers: an evaluation of published English-language guidelines [PDF]

, 2014
Background People intending to travel may seek information on malaria prevention from a range of sources. To ensure the best protection, this information needs to be reliable, up-to-date, consistent, and useful to their decision making.
Garner, Paul, Kliner, Merav, Poole, Kristina, Sinclair, David   +3 more
core   +3 more sources

Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru

Brazilian Journal of Infectious Diseases, 2001
The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (MalaroneTM) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru.
Llanos-Cuentas A., Campos P., Clendenes M., Canfield C. J., Hutchinson D. B. A.   +4 more
doaj  

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. [PDF]

, 2014
Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues.
Borboa, Rachel, Campo, Brice, Chatterjee, Arnab K, Chen, Zhong, Diagana, Thierry T, Gagaring, Kerstin, Glynne, Richard J, Klooster, Els J, Kocken, Clemens HM, Kuhen, Kelli, Leroy, Didier, Luty, Adrian, McNamara, Case W, Nagle, Advait, Plouffe, David M, Remarque, Edmond J, Roland, Jason, Sauerwein, Robert, Thomas, Alan W, van Amsterdam, Sandra M, van den Berg, Alexander, van Gemert, Geert-Jan, Voorberg-van der Wel, Annemarie, Winzeler, Elizabeth A, Yeung, Bryan KS, Zeeman, Anne-Marie   +25 more
core   +1 more source

A Novel Inhibitor against the Bromodomain Protein 1 of the Malaria Pathogen Plasmodium Falciparum

ChemMedChem, Volume 20, Issue 11, June 2, 2025.
This article presents the development of a first‐in‐class inhibitor targeting the bromodomain protein PfBDP1 in Plasmodium falciparum, the deadliest variant of the malaria‐causing Plasmodium parasites. Through structure‐based drug design, the inhibitor interactions were characterized via X‐ray crystallography and isothermal titration calorimetry ...
Marius Amann, Robin Warstat, Kay Kristin Rechten, Philip Theuer, Magdalena Schustereder, Sophie Clavey, Bernhard Breit, Oliver Einsle, Martin Hügle, Michaela Petter, Stefan Günther   +10 more
wiley   +1 more source

Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites

Malaria Journal, 2007
Background The antimalarial drug atovaquone specifically targets Plasmodium falciparum cytochrome b (Pfcytb), a mitochondrial gene with uniparental inheritance.
Henry Marie-Claire, Assi Serge-Brice, Menard Didier, Fandeur Thierry, Jambou Ronan, Randrianarivelojosia Milijaona, Legrand Eric, Khim Nimol, Ekala Marie-Thérèse, Rogier Christophe, Bouchier Christiane, Mercereau-Puijalon Odile   +11 more
doaj   +1 more source